Your Current Practice Needs Modification
Your dosing of oral Prometrium 100 mg nightly is incorrect for all three indications you mentioned. The evidence strongly supports vaginal progesterone (not oral) at 200 mg daily or 90 mg gel for short cervix, and 17-OHPC (not oral progesterone) for history of preterm birth, while progesterone is not recommended for recurrent miscarriage prevention in singleton pregnancies 1.
Route and Dose Matter Critically
The most recent SMFM guidelines (2024) are explicit about which formulation works for which indication 1:
For Short Cervix (≤25 mm, no prior PTB):
- Vaginal progesterone is recommended at either 200 mg micronized capsules or 90 mg gel daily
- Specifically for cervical length ≤20 mm diagnosed before 24 weeks (GRADE 1A recommendation)
- Consider for 21-25 mm based on shared decision-making (GRADE 1B)
- Oral progesterone is NOT the studied or recommended formulation 1
For History of Preterm Birth:
- 17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg IM weekly is the recommended agent, starting at 16-20 weeks until 36 weeks 2
- Vaginal progesterone has NOT been proven effective for this indication in multiple RCTs including the large OPPTIMUM trial 2
- Oral progesterone is not recommended for this indication
For Recurrent Miscarriage:
- Progesterone is generally not recommended for prevention of recurrent pregnancy loss in singleton pregnancies
- The evidence base focuses on preterm birth prevention, not early pregnancy loss
Why Your Current Practice Is Problematic
The dose is too low: Even in studies examining oral micronized progesterone, effective doses were 100 mg four times daily (400 mg total), not 100 mg once daily 3, 4. Your current dose is 25% of what was studied.
The route is wrong: The highest quality evidence and current guidelines specifically recommend:
- Vaginal administration for short cervix (not oral) 1
- Intramuscular 17-OHPC for prior preterm birth (not oral progesterone) 2
The formulation matters: While some research studies have examined oral micronized progesterone at 400 mg daily and shown benefit 3, 4, these are not the formulations endorsed by current SMFM guidelines. The 2024 SMFM guidelines specifically state "The most studied formulations of vaginal progesterone are 90-mg (8%) progesterone gel and 200-mg micronized progesterone capsules" 1.
What You Should Be Doing Instead
Algorithm for Progesterone Use:
Step 1: Identify the specific indication
Short cervix (≤25 mm) on transvaginal ultrasound at 18-24 weeks, NO prior PTB:
- Prescribe vaginal progesterone 200 mg daily (or 90 mg gel)
- Start when short cervix diagnosed, continue until 36-37 weeks
- Strongest evidence for CL ≤20 mm 1
History of prior spontaneous preterm birth (20-36 6/7 weeks):
- Prescribe 17-OHPC 250 mg IM weekly
- Start at 16-20 weeks, continue until 36 weeks
- Do NOT switch to vaginal progesterone if cervix shortens later 2
Recurrent miscarriage (early pregnancy loss):
- Progesterone is NOT routinely recommended
- Consider other etiologies and interventions
Step 2: Common pitfall to avoid
Do not combine or switch between formulations without clear evidence. If a patient on 17-OHPC develops a short cervix, continue the 17-OHPC rather than switching to vaginal progesterone 2.
Critical Caveats
17-OHPC was withdrawn from FDA approval in 2023 due to lack of efficacy in the PROLONG trial, though it remains available as compounded formulations. The 2024 SMFM guidelines recommend against 17-OHPC for short cervix specifically, but the 2017 guidance still supports it for prior PTB history 2, 1
Oral progesterone at any dose is not guideline-recommended for preterm birth prevention, despite some positive research studies 3, 4. The discrepancy exists because guidelines prioritize the largest, most rigorous trials and meta-analyses
Vaginal progesterone efficacy diminishes after 24 weeks - recent data suggests no benefit when short cervix is diagnosed beyond 24 weeks 5